Skip to content

John Mascarenhas, MD, discusses the phase 3 SENTRY trial
Which AML patients get lasting benefit from olutasidenib?
Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL
Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials
Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma

Insider Reader Survey

Join SOHO

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Cellular Therapy

Cellular Therapy Multiple Myeloma SOHO Insider Podcast

Dr. Thomas Martin interviews 1st US patient treated with cilta-cel

by Leah Sherwood
January 9, 2026
0 Comments

ASH 2025 Cellular Therapy Leukemia Acute Myeloid Leukemia

Dr. Gwen Nichols, of Blood Cancer United, talks financial toxicity in blood cancer care

by Leah Sherwood
January 9, 2026
0 Comments

ASH 2025 Cellular Therapy Multiple Myeloma News

Earlier lines of cilta-cel linked to better immune fitness in myeloma

by Leah Sherwood
January 8, 2026
0 Comments

Lymphoma Roundtable ASH 2025 Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

What are the therapeutic combinations in large cell lymphoma?

by SOHO Insider Editors
January 6, 2026
0 Comments

ASH 2025 Cellular Therapy Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Aggressive B-Cell Lymphomas

Dr. Avalos highlights ASH 2025 takeaways, the future of blood cancer

by Leah Sherwood
January 5, 2026
0 Comments

Cellular Therapy Lymphoma News

US FDA approves liso-cel in relapsed or refractory MZL

by SOHO Insider Editors
December 4, 2025
0 Comments

Multiple Myeloma News SOHO 2025 Cellular Therapy Multiple Myeloma News

Dr. Sundar Jagannath defines ‘cure’ in multiple myeloma

by Leah Sherwood
November 30, 2025
0 Comments

Trending now Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas SOHO Insider Podcast

Tara Graff, DO, talks community care and the CAR-T vs bispecific debate

by Leah Sherwood
November 26, 2025
0 Comments

Cellular Therapy Lymphoma Mantle Cell Lymphoma

Liso-cel receives expanded approval in R/R MCL by European Commission

by SOHO Insider Editors
November 24, 2025
0 Comments

SBBC Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas Meeting News

A 2025 lymphoma snapshot from Julie Vose, MD, MBA

by Leah Sherwood
November 19, 2025
0 Comments

1
2
3
4
5
6
...
8

Top Categories

Cellular Therapy

74

Leukemia

113

Lymphoma

128

Multiple Myeloma

97

Myelodysplastic Syndromes

39

Myeloproliferative Neoplasms

23

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Cellular Therapy

Dr. Thomas Martin interviews 1st US patient treated with cilta-cel

Dr. Gwen Nichols, of Blood Cancer United, talks financial toxicity in blood cancer care

Earlier lines of cilta-cel linked to better immune fitness in myeloma

What are the therapeutic combinations in large cell lymphoma?

Dr. Avalos highlights ASH 2025 takeaways, the future of blood cancer

US FDA approves liso-cel in relapsed or refractory MZL

Dr. Sundar Jagannath defines ‘cure’ in multiple myeloma

Liso-cel receives expanded approval in R/R MCL by European Commission

A 2025 lymphoma snapshot from Julie Vose, MD, MBA

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

John Mascarenhas, MD, discusses the phase 3 SENTRY trial

Which AML patients get lasting benefit from olutasidenib?

Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

Cellular Therapy

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms